Josh Schimmer
Stock Analyst at Cantor Fitzgerald
Total Price Targets
7
Stocks Covered
7
Sectors
Healthcare
Most Recent
Mar 10, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Josh Schimmer
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| SEPN | Septerna, Inc. | $60.00 | $23.71 | +153.1% | 1 | Mar 10, 2026 |
| NBIX | Neurocrine Biosciences, Inc. | $195.00 | $131.64 | +48.1% | 1 | Mar 10, 2026 |
| XENE | Xenon Pharmaceuticals Inc. | $55.00 | $56.81 | -3.2% | 1 | Nov 4, 2025 |
| NUVL | Nuvalent, Inc. | $135.00 | $99.45 | +35.7% | 1 | Oct 15, 2025 |
| PVLA | Palvella Therapeutics, Inc. | $30.00 | $125.87 | -76.2% | 1 | Dec 18, 2024 |
| SPRY | ARS Pharmaceuticals, Inc. | $30.00 | $8.56 | +250.5% | 1 | Aug 19, 2024 |
| FDMT | 4D Molecular Therapeutics, Inc. | $40.00 | $9.17 | +336.2% | 1 | Apr 5, 2022 |
Recent Activity
- Mar 10, 2026— Set$60.00price target onSEPN(Septerna, Inc.)
- Mar 10, 2026— Set$195.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Nov 4, 2025— Set$55.00price target onXENE(Xenon Pharmaceuticals Inc.)
- Oct 15, 2025— Set$135.00price target onNUVL(Nuvalent, Inc.)
- Dec 18, 2024— Set$30.00price target onPVLA(Palvella Therapeutics, Inc.)
- Aug 19, 2024— Set$30.00price target onSPRY(ARS Pharmaceuticals, Inc.)
- Apr 5, 2022— Set$40.00price target onFDMT(4D Molecular Therapeutics, Inc.)
Frequently Asked Questions
Who is Josh Schimmer?
Josh Schimmer is a stock analyst at Cantor Fitzgerald covering 7 stocks primarily in Healthcare. They have issued 7 price targets since Apr 5, 2022.
What stocks does Josh Schimmer cover?
Josh Schimmer currently covers 7 stocks, including SEPN, NBIX, XENE, NUVL, PVLA.
What is Josh Schimmer's latest price target?
Josh Schimmer's most recent price target was $60.00 on SEPN (Septerna, Inc.), set on Mar 10, 2026.
What is Josh Schimmer's highest price target?
Josh Schimmer's highest issued price target is $195.00 on NBIX, set on Mar 10, 2026.
More Analysts at Cantor Fitzgerald
Coverage based on publicly published price targets. Not investment advice.